

NEW SILKROUTES GROUP LIMITED AND ITS SUBSIDIARIES Registration Number: 199400571K

Condensed Interim Financial Statements For the nine months Ended 31 March 2023

Table of Contents

		Page
A.	Condensed Interim Consolidated Statement of Profit or Loss and Other Comprehensive Income	1
B.	Condensed Interim Statements of Financial Position	3
C.	Condensed Interim Statements of Changes in Equity	5
D.	Condensed Interim Consolidated Statement of Cash Flows	8
E.	Notes to the Condensed Interim Consolidated Financial Statements	10
F.	Other Information Required by Listing Rule Appendix 7.2	26

CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

	Note	3 months ended 31 March 2023 Unaudited S\$'000	3 months ended 31 March 2022 Unaudited S\$'000 Re-presented	%	9 months ended March 2023 Unaudited S\$'000	9 months ended March 2022 Unaudited S\$'000 Re-presented	%
Revenue	4	6,472	9,519	(32%)	25,479	30,627	(17%)
Other income		2,223	254	776%	2,632	990	166%
Purchases of finished goods		(3,645)	(5,487)	(34%)	(14,364)	(18,309)	(22%)
Changes in inventories of finished							
goods		253	(79)	(422%)	109	(192)	(157%)
Employee benefits expense		(1,978)	(2,977)	(34%)	(7,537)	(8,616)	(13%)
Amortisation of intangible assets		(32)	(31)	3%	(95)	(93)	2%
Depreciation of property, plant and							
equipment		(154)	(282)	(45%)	(458)	(556)	(18%)
Depreciation of right-of-use assets		(400)	(535)	(25%)	(1,350)	(1,576)	(14%)
(Write-back)/impairment loss on							
trade and other receivables		_	_	n.m.	(61)	1	n.m.
Other operating expenses		(392)	(37,416)	(99%)	(493)	(38,510)	(99%)
Finance costs		(154)	(236)	(35%)	(758)	(765)	(1%)
Profit/(loss) before taxation	6	2,193	(37,270)	(106%)	3,104	(36,999)	(108%)
Taxation	7	(115)	(168)	(32%)	(301)	(350)	(14%)
Profit/(loss) for the period		2,078	(37,438)	(106%)	2,803	(37,349)	(108%)

n.m.: Not Meaningful See accompanying notes to condensed interim financial statements.

CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (CONT'D)

	3 months ended 31 March 2023	3 months ended 31 March 2022		9 months ended March 2023	9 months ended March 2022	
	Unaudited S\$'000	Unaudited S\$'000 Re-presented	%	Unaudited S\$'000	Unaudited S\$'000 Re-presented	%
Other comprehensive income/(loss):						
Item that may be reclassified subsequently to profit of loss:						
Foreign currency translation gain/(loss) on consolidation Other comprehensive	8	384	(98%)	648	(62)	n.m.
income/(loss) for the financial period, net of tax	8	384	(98%)	648	(62)	n.m.
Total comprehensive income/(loss) for the financial	2,086	(27.054)	(1060/)	2 451	(27.411)	(1000/)
period	2,080	(37,054)	(106%)	3,451	(37,411)	(109%)
Profit/(loss) attributable to:						
Owners of the Company	1,495	(37,839)	(104%)	1,564	(38,578)	(104%)
Non-controlling interests	583	401	45%	1,239	1,229	1%
-	2,078	(37,438)	(106%)	2,803	(37,349)	(108%)
Total comprehensive income/(loss)attributable to:						
Owners of the Company	1,503	(37,513)	(104%)	2,151	(38,578)	(106%)
Non-controlling interests	583	459	27%	1,300	1,167	11%
	2,086	(37,054)	(106%)	3,451	(37,411)	(109%)
Profit/(loss) per share attributable to owners of the Company (cent)						
- Basic and diluted	0.72	(18.15)		0.75	(18.51)	

n.m.: Not Meaningful See accompanying notes to condensed interim financial statements.

CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION

	Note	31 March 2023 Unaudited S\$'000	Group 30 June 2022 Audited S\$'000 Re-presented	1 July 2021 Audited S\$'000 Re-presented	31 March 2023 Unaudited S\$'000	Company 30 June 2022 Audited S\$'000 Re-presented	1 July 2021 Audited S\$'000 Re-presented
ASSETS							
Non-current assets							
Property, plant and							
equipment		2,269	2,074	4,302	18	5	12
Intangible assets	10	7,708	7,809	26,126	-	-	289
Right-of-use assets		1,266	1,998	5,224	335	-	577
Subsidiaries		-	-	-	24,256	24,256	28,294
Prepayments		248	347	1,008	-	-	1,008
Long-term receivables		-	-	475	-	-	-
Deferred tax assets		50	-	50	-	-	-
Total non-current assets		11,541	12,228	37,185	24,609	24,261	30,180
Current assets							
Inventories		1,430	1,759	3,264	-	-	-
Trade and other							
receivables		10,112	6,169	9,037	1,897	281	553
Prepayments		1,268	981	551	141	-	309
Cash and bank balances		1,726	2,098	8,885	824	-	97
Fixed deposits		32	53	559	-	<u>-</u>	-
		14,568	11,060	22,296	2,862	281	959
Disposal group classified		1	10.410				
as held for sale		16,164	19,410	- 22.206	- 2.062	- 201	
Total current assets		30,732	30,470	22,296	2,862	281	959
Total assets		42,273	42,698	59,481	27,471	24,542	31,139
EQUITY AND LIABILITIES							
EQUITY							
Share capital	11	120,784	120,784	118,553	120,784	120,784	118,553
Treasury shares	12	(1,182)	(1,182)	(1,160)	(1,182)	(1,182)	(1,160)
Other reserves		(3,477)	(4,064)	(3,513)	62	62	60
Accumulated losses		(143,348)	(144,912)	(94,760)	(141,524)	(142,256)	(95,668)
Equity attributable to equity holder of the							
Company		(27,223)	(29,374)	19,120	(21,860)	(22,592)	21,785
Non-controlling interests		932	429	1,409	-	-	
Total equity		(26,291)	(28,945)	20,529	(21,860)	(22,592)	21,785

CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION (CONT'D)

	Note	31 March 2023 Unaudited S\$'000	Group 30 June 2022 Audited S\$'000 Re-presented	1 July 2021 Audited S\$'000 Re-presented	31 March 2023 Unaudited S\$'000	Company 30 June 2022 Audited S\$'000 Re-presented	1 July 2021 Audited S\$'000 Re-presented
LIABILITIES							
Non-current liabilities							
Borrowings	13	981	511	2,070	-	-	-
Lease liabilities		370	-	1,804	370	-	372
Deferred tax liabilities		-	37	203	-	-	-
Other payables				7,710	-		
Total non-current							
liabilities		1,351	548	11,787	370	-	372
Current liabilities							
Trade and other payables		10,707	6,992	10,506	12,555	9,555	8,763
Contract liabilities		10,707	0,772	206	12,333	-	-
Borrowings	13	9,540	9,525	14,834	_	_	_
Financial guarantee		2,010	,,,,,,	- 1,00			
liabilities		36,406	37,579	-	36,406	37,579	-
Lease liabilities		, -	-	1,132	, -	, <u> </u>	219
Current income tax payable		-	-	487	-	_	-
		56,653	54,096	27,165	48,961	47,134	8,982
Liabilities directly associated with disposal group classified as held		,	,	•	,	•	,
for sale		10,560	16,999	-	-	-	-
Total current liabilities		67,213	71,095	27,165	48,961	47,134	8,982
Total liabilities		68,564	71,643	38,952	49,331	47,134	9,354
Total equity and liabilities		42,273	42,698	59,481	27,471	24,542	31,139

NEW SILKROUTES GROUP LIMITED AND ITS SUBSIDIARIES CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

	<> Attributable to owners of the Company>								
Group	Share capital S\$'000	Treasury shares S\$'000	Foreign currency translation reserve S\$'000	Capital reserve S\$'000	Other reserves S\$'000	Accumulated losses S\$'000	Total S\$'000	Non- controlling interests S\$'000	Total equity S\$'000
Balance as at 1 July 2022	120,784	(1,182)	799	62	(4,925)	(144,912)	(29,374)	429	(28,945)
Profit for the financial period Other comprehensive income	-	-	-	-	-	1,564	1,564	1,239	2,803
- Foreign currency translation differences	-	-	587		-		587	61	648
Total comprehensive income for the financial period	-	-	587	-	-	1,564	2,151	1,300	3,451
Contributions by and distributions to owners									
- Dividends	-	-	-	-	-	-	-	(658)	(658)
Transactions with owners in their own capacity as owners	-	-	-	-	-	-	-	(658)	(658)
Disposal of a subsidiary	-	-	-	-	-	-	-	(139)	(139)
Balance as at 31 March 2023	120,784	(1,182)	1,386	62	(4,925)	(143,348)	(27,223)	932	(26,291)

See accompanying notes to condensed interim financial statements.

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (CONT'D)

	<>								
Group	Share capital S\$'000	Treasury shares S\$'000	Foreign Currency translation reserve S\$'000	Capital reserve S\$'000	Other reserves S\$'000	Accumulated losses S\$'000	Total S\$'000	Non- controlling interests S\$'000	Total equity S\$'000
Re-presented Balance as at 1 July 2021	118,553	(1,160)	1,260	60	(4,833)	(94,760)	19,120	1,409 1,229	20,529 (37,349)
(Loss)/profit for the financial periodOther comprehensive loss:Foreign currency translation differences	-	_	_	_	_	(38,578)	(38,578)	(62)	(62)
Total comprehensive (loss)/income for the financial period	-	-	-			(38,578)	(38,578)	1,167	(37,411)
Contributions by and distributions to owners - Dividends	-	_	-	_	-	-	-	(638)	(638)
Transactions with owners in their own capacity as owners	-	-	-	-	-	-	-	(638)	(638)
Effect of change in presentation currency	1,349	(13)	15	1	(55)	(1,249)	48	18	66
Balance as at 31 March 2022	119,902	(1,173)	1,275	61	(4,888)	(134,587)	(19,410)	1,956	(17,454)

See accompanying notes to condensed interim financial statements.

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (CONT'D)

Company	Share capital S\$'000	Treasury shares S\$'000	Capital reserve S\$'000	Accumulated losses S\$'000	Total equity S\$'000
Balance as at 1 July 2022 Profit for the year, representing total comprehensive profit for the financial period	120,784	(1,182)	62	(142,256) 732	(22,592) 732
Balance as at 31 March 2023	120,784	(1,182)	62	(141,524)	(21,860)
Re-presented Balance as at 1 July 2021 Loss for the year, representing total comprehensive loss for the financial period	118,553	(1,160)	60	(95,668) (37,648)	21,785 (37,648)
Effect of change in presentation currency	1,349	(13)	1	(1,256)	81
Balance as at 31 March 2022	119,902	(1,173)	61	(134,572)	(15,782)

CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

	9 months ended 31 March 2023 Unaudited S\$'000	9 months ended 31 March 2022 Unaudited S\$'000 Re-presented
Cash flows from operating activities Profit/(loss) before taxation:	3,104	(36,999)
Tone (loss) before taxation.	3,104	(30,999)
Adjustments for:		
Amortisation of intangible assets	95	93
Depreciation of property, plant and equipment	458	556
Depreciation of right-of-use assets	1,350	1,576
Interest expense	758	765
Impairment losses/(write-back) recognised on trade and		
other receivables	61	(1)
Loss on disposal of subsidiary	(545)	-
Recognition of financial guarantee liabilities	-	37,140
Unrealised foreign exchange differences	(1,855)	299
Operating cash flows before working capital changes:	3,426	3,429
Changes in inventories	269	594
Changes in trade and other receivables	(4,248)	(2,251)
Changes in prepayments	(188)	(605)
Changes in trade and other payables	2,934	(426)
Changes in contract liabilities	-	(26)
Cash generated from operations	2,193	715
Income tax paid	-	(371)
Net cash generated from operating activities	2,193	344
Cash flows from investing activities		
Acquisition of intangible assets	-	(375)
Purchase of property, plant and equipment	(438)	(81)
Net cash inflow from the disposal of subsidiary	1,028	-
Net cash generated from/(used in) investing activities	590	(456)

CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS (CONT'D)

	Group		
	9 months ended 31 March 2023 Unaudited S\$'000	9 months ended 31 March 2022 Unaudited S\$'000 Re-presented	
Cash flows from financing activities			
Dividends paid to the non-controlling interests of the			
subsidiaries	(658)	(638)	
Interest paid	(359)	(602)	
Proceeds from loans	-	283	
Repayment of loans	(1,779)	(1,679)	
Repayment of lease liabilities	(686)	(1,009)	
Net cash used in financing activities	(3,482)	(3,645)	
Net decrease in cash and cash equivalents	(699)	(3,757)	
Cash and cash equivalents at beginning of financial period Exchange differences on translation of cash and	5,679	8,795	
cash equivalents	(967)	21	
Cash and cash equivalents at end of financial period	4,013	5,059	
Cash and cash equivalents comprise the following:			
Cash and bank balances and fixed deposits	4,046	5,141	
Less: Cash restricted in use	(32)	(82)	
Less: Fixed deposits pledged	(1)	-	
Cash and cash equivalents at end of financial period	4,013	5,059	

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1 Corporate information

New Silkroutes Group Limited (the "Company") (Co. Reg. No. 199400571K) is a limited liability company incorporated and domiciled in Singapore. The address of its registered office and principal place of business is at 456 Alexandra Road, #24-01 Fragrance Empire Building, Singapore 119962. The Company is listed on the Singapore Exchange Securities Trading Limited. These condensed interim consolidated financial statements as at and for the nine months ended 31 March 2023 comprise the Company and its subsidiaries (collectively, the "Group").

The principal activities of the Company are that of an investment holding Company. The principal activities of the Group as at 31 March 2023 were:

- (a) Distributors of health supplements and Chinese proprietary medicine, providers of clinical management services, and healthsciences consultants;
- (b) Dental services;
- (c) General medical services and aesthetic clinic;
- (d) Medical and dental supplies;
- (e) Manufacture of non-woven fabric;
- (f) Management services and investment holding.

Proposed Restructuring Exercise

The Company on 9 January 2023 applied to the High Court of the Republic Singapore (the "Court") for moratorium protection pursuant to Section 64 of the Insolvency, Restructuring, and Dissolution Act 2018 ("IRDA"). On 6 February 2023, the Court granted the moratorium protection sought until 9 July 2023, which was subsequently extended to 9 October 2023, and further extended to 9 December 2023. The purpose of the moratorium is to facilitate the reorganisation of the liabilities and business of the Company and the Group, to preserve the value of the Group's core business and maintain a sustainable capital structure.

The Company refers to its announcements dated 6 September 2023, 20 October 2023, 24 October 2023, 25 October 2023, 30 October 2023 and 1 November 2023. Following the proposal of a "prepackaged" scheme of arrangement pursuant to Section 71 of the IRDA (the "**Proposed Scheme**") to its creditors, vote solicitation and adjudication of proof of debt forms have been completed by the Scheme Managers and the Company has applied to the Court, pursuant to Section 71(1) of the IRDA, for an order approving the Proposed Scheme. The Ontario Whitewash Waiver (as defined in the announcement dated 24 October 2023) has also been granted by the Securities Industry Council subject to the conditions disclosed in the announcement.

The restructuring exercise is still ongoing as at the date of these financial statements.

2 Basis of preparation

The condensed interim financial statements are for the nine months ended 31 March 2023 have been prepared in accordance with SFRS(I) 1-34 *Interim Financial Reporting* issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last audited financial statements for the year ended 30 June 2022.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

2 Basis of preparation (cont'd)

Prior to 1 July 2022, the United States Dollar ("US\$") was regarded as the functional currency of the Company and the consolidated financial statements were also presented in US\$. The Company had, having reviewed its business and operating environment, changed its functional currency from US\$ to Singapore Dollar ("SGD" or "S\$") during the financial year ended 30 June 2023. The change in functional currency of the Company was applied prospectively from the date of change on 1 July 2022, in accordance with SFRS(I) 1-21 The Effects of Changes in Foreign Exchange Rates.

In conjunction with the change in functional currency, the Company and the Group had also changed its presentation currency to S\$. The change in presentation currency has been applied retrospectively in accordance with SFRS(I) 1-8 Accounting Policies, Changes in Accounting Estimates and Errors. The comparative figures of the Group and the Company in these financial statements have been represented in S\$ in order to provide meaningful comparable information.

The condensed interim financial statements are presented in SGD or S\$, which is the Company's functional currency and all values in the tables are rounded to the nearest thousand (S\$'000), except when otherwise indicated.

2.1 New and amended standards adopted by the Group

A number of amendments to Standards has become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

2.2 Use of judgements and estimates

Critical judgements in applying the entity's accounting policies

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income, and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the financial year ended 30 June 2022.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

Going concern assumption

During the financial period ended 31 March 2023, the Group reported a net profit of \$\$3,104,000 (31 March 2022: net loss of \$\$36,999,000) and the Company reported a net profit of \$\$732,000 (31 March 2022: net loss of \$\$37,648,000). The Group's and the Company's current liabilities exceeded the current assets by \$\$36,481,000 (30 June 2022: \$\$41,173,000) and \$\$46,099,000 (30 June 2022: \$\$46,853,000) respectively. These conditions indicate the existence of material uncertainties that may cast significant doubts about the Group's and the Company's abilities to continue as going concerns.

2 Basis of preparation (cont'd)

2.2 Use of judgements and estimates (cont'd)

Critical judgements in applying the entity's accounting policies (cont'd)

Going concern assumption (cont'd)

The Directors of the Company are of the view that the going concern assumption is appropriate for the preparation of these financial statements based on the following assessments:

- (a) As part of the debt restructuring exercise, 2810198 Ontario Inc ("Ontario"), the largest creditor of the Group, planned to convert its debt into equity in the Company through the company scheme and will become the controlling shareholder of the Company. Ontario is in full support by providing the super priority loan to the Company. Ontario has plans to use the Company as a vehicle to hold various businesses and the investments post debt restructuring. The future value of the Company will be underpinned by the value of business and investments Ontario intends on injecting into the Company.
- (b) The Company on 9 January 2023 applied to the Court for moratorium protection pursuant to Section 64 of the IRDA. On 6 February 2023, the Court granted the moratorium protection sought until 9 July 2023, which was subsequently extended to 9 October 2023, and further extended to 9 December 2023. The purpose of the moratorium is to facilitate the reorganisation of the liabilities and business of the Company and the Group, to preserve the value of the Group's core business and maintain a sustainable capital structure.
 - The Company refers to its announcements dated 6 September 2023, 20 October 2023, 24 October 2023, 25 October 2023, 30 October 2023 and 1 November 2023. Following the proposal of the Proposed Scheme to its creditors, vote solicitation and adjudication of proof of debt forms have been completed by the Scheme Managers and the Company has applied to the Court, pursuant to Section 71(1) of the IRDA, for an order approving the Proposed Scheme. The Ontario Whitewash Waiver (as defined in the announcement dated 24 October 2023) has also been granted by the Securities Industry Council subject to the conditions disclosed in the announcement.
- (c) Funding will be raised from potential investor amounting to S\$4 million, of which (i) S\$200,000 shall be utilised to fund the cash distribution under the Proposed Scheme, and (ii) S\$3.8 million shall be utilised to fund amongst others the Group's working capital for the next 2 years (from April 2023 to April 2025).

The Directors are of the opinion that the above would allow the Group to restructure its operations and enable the Group and the Company to pay their debts as and when they fall due.

For these reasons, the financial statements have been prepared on the assumptions that the Group and Company will continue as going concerns. The financial statements did not include any adjustments that may result in the event that the Group and Company are unable to continue as going concerns. In the event that the Group and Company are unable to continue in operational existence for the foreseeable future, the Group and Company may be unable to realise its assets and discharge its liabilities in the normal course of business and adjustments may have to be made to reflect the situation that assets may need to be realised other than in the normal course of business and at amounts which could differ significantly from the amounts at which they are currently recorded in the statements of financial position. In addition, the Group and Company may have to provide for further liabilities that might arise, and to reclassify non-current assets and liabilities as current assets and liabilities. No such adjustments have been made in the financial statements."

2 Basis of preparation (cont'd)

2.2 Use of judgements and estimates (cont'd)

Critical judgements in applying the entity's accounting policies (cont'd)

Control over Shanghai Fengwei Garment Accessory Co., Ltd. ("Shanghai Fengwei")

Pursuant to the Management Agreement, the Company assigned the management rights and the profits of Shanghai Fengwei during the period from 1 January 2020 to 31 December 2021 to the Entity. All post-tax profits or losses during the aforesaid period, whether in excess of or less than the Consideration, shall be attributable to or borne by the Entity. In return, the Entity would retain the net profit or loss after tax generated by Shanghai Fengwei for 2020 and 2021.

The directors of the Company made an assessment that Shanghai Fengwei's management continues to manage the operations and business activities of Shanghai Fengwei and that the Group has control over Shanghai Fengwei in accordance with the definition of control and the related guidance set out in SFRS(I) 10 Consolidated Financial Statements. Accordingly, Shanghai Fengwei remains a subsidiary of the Group.

Key sources of estimation uncertainty

Information about assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next financial period are included in the following notes:

Impairment of trade and other receivables

The Group has applied the simplified approach within SFRS(I) 9, based on lifetime ECL, in determining the loss allowance on trade receivables at the end of each reporting period.

The Group determined the ECL of trade receivables by categorising them based on days past due for groupings of various customer segments that have similar loss patterns. The ECL rates for each category of the debtors are estimated based on historical credit loss experience adjusted as appropriate to reflect current condition and forward-looking information which is based on assumptions and forecasts of future economic conditions with consideration of the impact of COVID-19 pandemic and how these conditions will affect the Group's ECL assessment.

As the calculation of loss allowance on trade receivables and contract assets is subject to assumptions and forecasts, any changes to these estimations will affect the amounts of loss allowance recognised and the carrying amounts of trade receivables and contract assets.

Impairment test for cash-generating unit containing goodwill and intangibles

A cash-generating unit ("CGU") to which goodwill has been allocated shall be tested for impairment annually, and whenever there is an indication that the unit may be impaired, by comparing the carrying amount of the CGU, including the goodwill, with the recoverable amount of the CGU. The recoverable amount is the higher of the CGU's fair value less costs of disposal and its value in use. Where the recoverable amount of the CGU is less than its carrying amount, such impairment loss is recognised in profit or loss.

2 Basis of preparation (cont'd)

2.2 Use of judgements and estimates (cont'd)

Key sources of estimation uncertainty (cont'd)

Impairment test for cash-generating unit containing goodwill and intangibles (cont'd)

Significant judgement and estimates by management are required in assessing: (i) whether the carrying amount of the CGU can be supported by its market value based on comparable assets or the net present value of future cash flows which are estimated based upon the continued use of the assets in the business; and (ii) the appropriate key assumptions to be applied in preparing cash flow projections including whether these cash flow projections are extrapolated using a suitable growth rate and then discounted using an appropriate discount rate. Changing the assumptions selected by management to determine the level of impairment, including the growth rate and discount rate assumptions in the cash flow projections, could materially affect the net present value used in the impairment test and as a result may potentially affect the Group's results. The carrying amounts of the Group's intangible assets, including goodwill, at the end of the reporting period, and the basis and assumptions used to determine the recoverable amount of the CGU, are disclosed in Note 10.

Impairment of investment in subsidiaries

At the end of each reporting period, the Company assesses whether there are any indications of impairment for investment in subsidiaries. The Company also assesses whether there is any indication that an impairment loss recognised in prior periods for investment in subsidiaries may no longer exist or may have decreased.

If any such indication exists, the Company estimates the recoverable amount of that asset. An impairment loss exists when the carrying value of an asset exceeds its recoverable amount, which is the higher of its fair value less costs to sell and its value in use. An impairment loss recognised in prior periods shall be reversed if there has been a change in the estimates used to determine the asset's recoverable amount since the last impairment loss was recognised.

Estimation of financial guarantee liabilities

Financial guarantees are financial instruments issued by the Company that requires the issuer to make specified payments to reimburse the holder for a loss it incurs because a specified debtor fails to make payments when due in accordance with the terms of a debt instrument.

Financial guarantee contract liabilities are initially measured at their fair values. Subsequently, they are measured at the higher of the loss allowance determined in accordance with SFRS (I) 9 and the amount initially recognised less, when appropriate, the cumulative amount of income recognised in accordance with the principles of SFRS (I) 15.

3 Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4 Segment and revenue information

For management purposes, the Group is organised into business units based on their products and services, and has three reportable operating segments as follows:

- Healthcare owns and operates clinics in Singapore providing complementary integrative therapies, runs employee healthcare benefits programmes, offers systems integration services to hospitals and healthcare facilities, owns and operates clinics in Singapore providing dental services, and distributes dental and medical supplies, and manufacturing of healthcare consumables.
- Others general corporate activities and others

The Group's executive directors monitor the operating results of its operating segments for the purpose of making decisions about resource allocation and performance assessment.

Information regarding the results of each reportable segment is included in the following table. Performance is measured based on segment profit/(loss) before taxation, as included in the internal management reports that are regularly reviewed by the Group's executive directors. Segment profit/(loss) is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within these industries.

4.1 Reportable segments

1 July 2022 to 31 March 2023	Healthcare Unaudited S\$'000	Per consolidated financial statements Unaudited S\$'000
Segment revenue - Sales to external customers	25,479	25,479
Segment results - Other income - Amortisation of intangible assets - Depreciation of property, plant and equipment - Depreciation of rights-of-use assets - Finance costs Segment profit	2,632 (95) (458) (1,350) (758) 2,803	2,632 (95) (458) (1,350) (758) 2,803
Segment assets and liabilities - Segment assets - Segment liabilities	42,273 68,564	42,273 68,564

4 Segment and revenue information (cont'd)

4.1 Reportable segments (cont'd)

1 July 2021 to 31 March 2022	Healthcare Unaudited S\$'000 Re-presented	Others Unaudited S\$'000 Re-presented	Per consolidated financial statements Unaudited S\$'000 Re-presented
Segment revenue			
- Sales to external customers	30,626	-	30,626
Segment results - Other income - Amortisation of intangible assets - Depreciation of property, plant and equipment * - Depreciation of rights-of-use assets - Other non-cash items - Finance costs Segment profit/(loss)	872 (93) (552) (1,402) (4) (563) 708	118 (4) (174) (37,148) (202) (37,707)	990 (93) (556) (1,576) (37,152) (765) (36,999)
Segment assets and liabilities - Segment assets - Segment liabilities - Capital expenditure	46,038 28,343 (82)	10,451 45,600	56,489 73,943 (82)

^{*} Comprises depreciation of property, plant and equipment included in changes in inventories of finished goods

4 Segment and revenue information (cont'd)

4.2 Disaggregation of revenue

	9 months ended 31 March 2023 Unaudited S\$'000	9 months ended 31 March 2022 Unaudited S\$'000 Re-presented
Healthcare products Healthcare services	13,512 11,967	17,312 13,315
	25,479	30,627

Geographical information:

	9 months ended 31 March 2023 Unaudited S\$'000	9 months ended 31 March 2022 Unaudited S\$'000 Re-presented
Australia	-	62
China	13,512	17,312
Singapore	11,967	13,253
	25,479	30,627

5 Financial assets and financial liabilities

5.1 Categories of financial instruments

Set out below is an overview of the financial assets and financial liabilities of the Group as at 31 March 2023 and 30 June 2022:

	Gr	oup	Com	pany
	31 March 2023 Unaudited S\$'000	30 June 2022 Audited S\$'000 Re-presented	31 March 2023 Unaudited S\$'000	30 June 2022 Audited \$\$'000 Re-presented
Financial assets Financial assets at amortised cost	14,880	13,052	2,721	281
Financial liabilities				
Lease liabilities	1,232	1,915	370	-
Financial liabilities at fair value				
through profit or loss	8,311	8,585	-	-
Financial guarantee liabilities	36,406	37,579	36,406	37,579
Financial liabilities at amortised				
cost	30,537	22,523	12,555	9,555

6 (Loss)/profit before taxation

6.1 Significant items

<u>Group</u>	9 months ended 31 March 2023 Unaudited S\$'000	9 months ended 31 March 2022 Unaudited S\$'000 Re-presented
Impairment loss/(write-back) recognised on trade and other receivables Recognition of financial guarantee liabilities	61	(1) (37,140)

6.2 Related party transactions

Other than as disclosed elsewhere in the interim financial statements, the following related party transactions took place between the Group and related parties during the financial period on terms agreed by the parties concerned:

Group	9 months ended 31 March 2023 Unaudited S\$'000	9 months ended 31 March 2022 Unaudited S\$'000 Re-presented
Interest expense Lease payments (rental)	163 531	162 579

7 Taxation

The Group calculates the period income tax expense using the tax rate that would be applicable to the expected total annual earnings. The major components of income tax expense in the condensed interim consolidated statement of profit or loss are:

<u>Group</u>	9 months ended 31 March 2023 Unaudited S\$'000	9 months ended 31 March 2022 Unaudited S\$'000 Re-presented
Current taxation: - Current period - Changes in estimates related to prior years	301	389
	301	389
Deferred taxation: - Origination and reversal of temporary differences	-	(39)
	301	350

8 Net asset value

	Gro	oup	Company	
	31 March 2023 Unaudited	30 June 2022 Audited Re-presented	31 March 2023 Unaudited	30 June 2022 Audited Re-presented
Net asset value per ordinary share (cent)	(13.06)	(14.09)	(10.49)	(10.84)

9 Disposal of subsidiaries

On 2 February 2023, the other shareholder of Crescent Dental Clinic Pte. Ltd., DentalTrendz JP Pte. Ltd., Trendz Dental Surgeons Pte. Ltd., L'ving Vine Dental Clinic Pte. Ltd., Dover Dental Surgery Pte. Ltd. and DentalTrendz Pte. Ltd. (the "**Trendz Clinics**") exercised the call option to purchase the Call Option Shares (as defined in the share purchase agreement dated 26 May 2017), being all of the HSI Dental Pte. Ltd. ("**HSID**")'s shares in each of the Trendz Clinics for an aggregate consideration of S\$1,280,000.

The Company accepted the shareholder's exercise of the call option and completion took place on 7 February 2023. Accordingly, HSID no longer holds any of the registered capital of the Trendz Clinics and the Trendz Clinics have ceased to be subsidiaries of the Company.

9 Disposal of subsidiaries (cont'd)

The effects of the disposal on the Group's financial statements are as shown below:

	9 months ended 31 March 2023 Unaudited
	S\$'000
Identifiable assets and liabilities	
Property, plant and equipment	181
Right-of-use assets	221
Cash and bank balances	252
Trade receivables	215
Other receivables	529
Total assets	1,398
Trade payables	85
Other payables	567
Lease liabilities	242
Current income tax payable	24
Deferred tax liabilities	10
Total liabilities	928
Identifiable net assets disposed	(469)
Goodwill disposed	(405)
Cash consideration	1,280
NCI Disposed	139
Deemed return of capital	(901)
Loss on disposal	(356)

The effects of the disposal of subsidiaries on the cash flows of the group is as below:

	9 months ended 31 March 2023 Unaudited \$\$'000
Cash consideration	1,280
Less: cash and cash equivalent in subsidiary disposed	(252)
Net cash inflow on disposal	1,028

10 Intangible assets

Group	Goodwill S\$'000	Customer relationship S\$'000	CMS Development costs S\$'000	Service right S\$'000	Trademark S\$'000	Other development cost S\$'000	Total S\$'000
Re-presented	54 000	50 000	54 000	S\$ 000	50 000	54 000	54 000
Cost:							
Balance at 1 July 2021	25,827	375	2,115	125	452	294	29,188
Additions	-	-	-	-	-	474	474
Written off	-	-	-	-	-	(768)	(768)
Exchange difference on translation	(526)	(17)	=	(3)	-	=	(546)
Reclassified to disposal group held for sales	(17,862)	-	-	-	-	-	(17,862)
Balance at 30 June 2022, 1 July 2022 and 31 March 2023	7,439	358	2,115	122	452	-	10,486
Accumulated amortisation:							
Balance at 1 July 2021	=	105	2,115	126	226	=	2,572
Amortisation	-	36	-	-	90	-	126
Impairment charge	6,052	-	-	-	-	-	6,052
Reclassified to disposal group held for sales	(6,052)	(17)	=	- (4)	-	-	(6,052)
Exchange difference on translation		(17)		(4)	-		(21)
Balance at 30 June 2022 and 1 July 2022	-	124	2,115	122	316	-	2,677
Amortisation	-	27	-	-	68	-	95
Exchange difference on translation	-	6	-	-	-	-	6
Balance at 31 March 2023	-	157	2,115	122	384	-	2,778
Carrying amount: Balance at 31 March 2023	7,439	201	-	-	68	-	7,708
Balance at 30 June 2022	7,439	234	-	-	136	-	7,809

10 Intangible assets (cont'd)

Impairment testing for a cash-generating unit containing goodwill

Goodwill that has an indefinite useful life are not subject to amortisation and are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it might be impaired. No impairment indicators were identified as at 31 March 2023 based on each CGU's business performance. The Group performed its annual impairment test in June 2022. The key assumptions used to determine the recoverable amount for the CGU were disclosed in the last audited financial statements for the year ended 30 June 2022. The Group tests goodwill annually for impairment or more frequently if there are indicators that goodwill might be impaired.

11 Share capital

	31 March 2023		30 June	2022
	Number of Amount shares S\$'000 Audited		Number of shares	Amount S\$'000 Unaudited Re-presented
Group and Company				Ke-pi esenteu
Issued and fully paid with no par value At beginning and end of interim period	211,908,869	120,784	211,908,869	120,784

The number of issued shares excluding treasury shares as at the end of the interim period was 208,464,669 (30 June 2022: 208,464,669).

The holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to one vote per share at shareholders' meetings. All shares rank equally with regard to the Company's residual assets.

The Company's subsidiaries do not hold any shares in the Company as of 31 March 2023 and 30 June 2022.

12 Treasury shares

	31 March 2023		30 Jun	e 2022
Group and Company	Number of shares	Amount S\$'000 Audited	Number of shares	Amount \$'000 Unaudited Re-presented
Issued and fully paid with no par value				
At beginning and end of interim period	3,444,200	(1,182)	3,444,200	(1,182)

13 Borrowings

	Group	
	31 March 2023 Unaudited S\$'000	30 June 2022 Unaudited S\$'000 Re-presented
Amount repayable within one year or on demand Secured Unsecured	9,540	9,525
Amount repayable after one year Secured Unsecured	981	511
	10,521	10,036

Loans from financial institutions are secured by the following:

- i. fixed deposits of the Group;
- ii. corporate guarantees by the Company and related parties;
- iii. charges over shares of certain subsidiaries of the Company;
- iv. personal guarantee(s) from a director of the Company and a former director of the Company and/or directors of subsidiaries;
- v. pledge over a director's land;
- vi. fixed and floating charge on all assets and undertakings of a subsidiary; and/or
- vii. certain property and equipment.

14 Financial guarantees liabilities

During the financial year ended 30 June 2022, the Company recognised financial guarantees liabilities amounting to S\$37,579,000 (2021: S\$Nil) in respect of the corporate guarantees provided to OCAP Management Pte. Ltd. and Iolani Shipping Limited.

On 24 May 2022, Ontario and the Company entered into Memorandum of Agreement and Ontario acquired all the rights, title, benefits and interests in financial guarantees relating to the loan and the lease financing arrangement. Upon execution of the deed of assignment on 18 July 2022, the financial guarantees liabilities were transferred to Ontario.

As disclosed in the Company's announcement dated 19 January 2023, the Company and Ontario have entered into a termination agreement to terminate the Memorandum of Agreement dated 24 May 2022 on the terms set out therein.

15 Subsequent events

<u>Disposal of 84 INC Pte. Ltd. ("84 INC")</u>, The Dental Hub@SG Pte. Ltd. ("TDH"), and NDC Consulting Pte. Ltd. ("NDC")

The Company refers to its announcements dated 3 October 2022, 20 December 2022, 4 January 2023 and 1 February 2023. Unless otherwise defined, capitalised terms used herein shall have the same meaning as ascribed in the 1 February 2023 announcement.

15 Subsequent events (cont'd)

Following the lapse and cessation of the business transfer agreement dated 3 October 2023 on 3 January 2023, 84 INC, TDH, NDC, and the Existing Shareholders on 1 February 2023 entered into the BTA for the disposal of the Business. The Parties are in the process of Completion.

Judicial Management of HSI Medical Pte. Ltd. ("HSIM")

The Company refers to its announcements dated 20 January 2023, 20 February 2023 and 17 November 2023 in relation to the judicial management of HSIM pursuant to Section 91 of the IRDA. HSIM has been discharged from judicial management with effect from 15 November 2023.

Incorporation of New Silkroutes Developments Pte. Ltd.

The Company has on 12 April 2023 incorporated a wholly owned direct subsidiary, New Silkroutes Developments Pte. Ltd..

<u>Disposal of Lily Aw Medical Services Pte Ltd, HL Family Clinic & Surgery (Bedok) Pte. Ltd., HL Dermahealth Aesthetic Clinic Pte. Ltd., HL Clinic Pte Ltd, HK Family Clinic & Surgery Pte. Ltd., and Dr Chua's Family Clinic Pte. Ltd. (the "**Medical Subsidiaries**")</u>

The Company refers to its announcements dated 3 May 2023 and 10 May 2023 in relation to, *inter alia*, the disposal of the Medical Subsidiaries by the Judicial Managers of HSIM. The disposals have been completed as at 5 May 2023. Accordingly, HSIM no longer holds any of the registered capital of the Medical Subsidiaries and the Medical Subsidiaries have ceased to be subsidiaries of the Company.

Acquisition of Hidderton Limited

The Company on 26 April 2023 acquired 100% of the equity of Hidderton Limited, a company registered in the British Virgin Islands, from FS Real Estate Investment Company Limited. Hidderton Limited holds 100% of the equity of FS Xiangshan Pte. Ltd., which in turn holds 100% of the equity of Beijing Xiefei Business Management Co., Ltd., which in turn holds 100% of the equity of Beijing Lunan Technology Co., Ltd., Pursuant to the acquisition, Hidderton Limited, FS Xiangshan Pte. Ltd., Beijing Xiefei Business Management Co., Ltd., and Beijing Lunan Technology Co., Ltd. have become subsidiaries of the Company.

Disposal of HSI Chinese Medicine

The Company refers to its announcements dated 12 May 2022 and 3 May 2023 in relation to the disposal of the assets and business of HSI Chinese Medical by HSI. The disposal has been completed as at 8 September 2023.

<u>Disposal of Wren Dental and Medical Supplies Pte. Ltd. ("WDMS") and Orange Orthodontics and Dentofacial Orthopaedics Pte. Ltd. ("OODO")</u>

The Company refers to its announcement dated 12 May 2023 in relation to the disposal of HSID's entire shareholding interest in WDMS and OODO. The disposal has been completed as at 12 May 2023. Accordingly, HSID no longer holds any of the registered capital of WDMS and OODO and WDMS and OODO have ceased to be subsidiaries of the Company.

Disposal of Shanghai Fengwei

The Company refers to its announcements dated 28 April 2023 and 21 July 2023 in relation to the proposed disposal of 100% of the equity of Shanghai Fengwei, which is ongoing.

15 Subsequent events (cont'd)

Proposed Restructuring Exercise

The Company on 9 January 2023 applied to the Court for moratorium protection pursuant to Section 64 of the IRDA. On 6 February 2023, the Court granted the moratorium protection sought until 9 July 2023, which was subsequently extended to 9 October 2023, and further extended to 9 December 2023. The purpose of the moratorium is to facilitate the reorganisation of the liabilities and business of the Company and the Group, to preserve the value of the Group's core business and maintain a sustainable capital structure.

The Company refers to its announcements dated 6 September 2023, 20 October 2023, 24 October 2023, 25 October 2023, 30 October 2023 and 1 November 2023. Following the proposal of the Proposed Scheme to its creditors, vote solicitation and adjudication of proof of debt forms have been completed by the Scheme Managers and the Company has applied to the Court, pursuant to Section 71(1) of the IRDA, for an order approving the Proposed Scheme. The Ontario Whitewash Waiver (as defined in the announcement dated 24 October 2023) has also been granted by the Securities Industry Council subject to the conditions disclosed in the announcement.

The restructuring exercise is still ongoing as at the date of these financial statements.

Super Priority Rescue Financing

The Company refers to the Company's announcements dated 10 May 2023, 18 May 2023, 24 May 2023, 3 July 2023 and 14 September 2023 regarding the proposed rescue financing to be provided by Ontario. The Company has obtained the order of court granting super priority status to the proposed financing of up to S\$5.9 million from Ontario to the Company (the "**DIP Facility**"), and on 14 September 2023, the Company has entered into a definitive facility agreement with Ontario in respect of the DIP Facility.

Voluntary Liquidation of Healthsciences International Pte. Ltd. ("HSI") and HSID

The Company refers to its announcement dated 29 September 2023 in relation to voluntary liquidation of HSI and HSID. HSI and HSID have been placed into creditors' voluntary liquidation on 29 September 2023, which is ongoing.

Acquisition of Tianjin Zhoushun Logistics Co., Ltd.

The Company refers to its announcements dated 18 September 2023 and 10 October 2023 in relation to the proposed acquisition of 100% of the equity of Tianjin Zhoushun Logistics Co., Ltd., which is ongoing.

OTHER INFORMATION REQUIRED BY LISTING RULE APPENDIX 7.2

1. Review

The condensed consolidated statement of financial position of New Silkroutes Group Limited and its subsidiaries as of 31 March 2023 and the related condensed consolidated statement of comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the nine-month period ended and certain explanatory notes have not been audited or reviewed.

Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion: -

(a) Updates on efforts taken to resolve each outstanding audit issue

The auditors have issued a disclaimer of opinion on the Group's financial statements for the financial year ended 30 June 2022 due to:

- i. Going concern assumptions
- ii. Management agreement entered by the Company and its wholly owned subsidiary, Shanghai Fengwei with Shanghai Minlin New Textile Materials Sales Centre, goodwill impairment assessment of Shanghai Fengwei and subsequent events of Shanghai Fengwei.
- iii. Investment in International Energy Group Pte. Ltd. ("IEG") concerning its valuation of the carrying amounts of assets and liabilities of IEG including Thai General Nice Coal and Coke Co., Ltd, a financial asset at fair value through other comprehensive income, as of the date of commencement of liquidation, and the resulting loss arising from deconsolidation of IEG and the impairment assessment of investment in IEG.
- iv. Financial guarantee liabilities in respect of corporate guarantees provided to third parties in prior years for a loan and a lease financing arrangement for IEG and TXZ Tankers Pte. Ltd..
- v. Guarantees and provisions in respect of banking facilities extended to its subsidiaries.
- vi. Classification and appropriateness of the disposal groups classified as held for sale.
- vii. Consideration payables in respect of the fair value change of the put liability arising from the acquisition of medical clinics.
- viii. Appropriateness of the impairment loss recognised for the investments in subsidiaries.
- ix. Opening balances as at 1 July 2021 for the financial year ended 30 June 2021 whose report dated 13 October 2021 contained a disclaimer of opinion.

Please refer to page 50 - 54 of the Company's Annual Report for the financial year ended 30 June 2022 for more information on these outstanding audit issues.

The Board has appointed KPMG Services Pte. Ltd. ("KPMG") as the independent reviewer to carry out an independent review. The independent review is still ongoing as of the date of this announcement. After the conclusion of the independent review of KPMG and finalisation of the discussion with the creditors, the Company will follow up with the appropriate accounting treatment on these outstanding audit issues.

1. Review (cont'd)

(a) Updates on efforts taken to resolve each outstanding audit issue (cont'd)

The Company has engaged a Financial Consultant to assist the Company in its preparation of the accounts and financial statements for the financial year ended 30 June 2023. The Financial Consultant will assist management in responding to the Company's auditor in connection with all the outstanding audit issues.

(b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

The Board confirms that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

2. Review of performance of the Group

Income Statement Review

Group revenue decreased to \$\$25.48 million for the third quarter ended 31 March 2023 ("**3Q23**") compared to \$\$30.63 million in the third quarter ended 31 March 2022 ("**3Q22**"). The Group's performance was mainly affected by a decline in demand for non-woven material as a result of heightened competition as China's economy began to recover from the Covid-19 pandemic.

Other income increased to S\$2.63 million in 3Q23 when compared to S\$0.99 million in 3Q22 mainly due to higher miscellaneous income received in 3Q23.

Purchases of finished goods and changes in inventories of finished goods expenses decreased to S\$14.36 million in 3Q23 from S\$18.31 million in 3Q22 and S\$0.11 million in 3Q23 from S\$0.19 million in 3Q22 respectively. The decrease is in line with the decrease in revenue for non-woven material.

Other operating expenses decreased to \$\$0.49 million in 3Q23, down from \$\$38.51 million in 3Q22 mainly due to recognition of financial guarantee liabilities arising from contingent liabilities and guarantees to third parties for loan, lease financing arrangement and boat charter agreement in 3Q22.

Financial Position Review

Property, plant and equipment increased to S\$2.27 million as at 31 March 2023 compared to S\$2.07 million as at 30 June 2022, mainly due to purchase of property, plant and equipment and depreciation of property, plant and equipment recognised.

Intangible assets decreased to S\$7.71 million as at 31 March 2023 compared to S\$7.81 million as at 30 June 2022 mainly due to amortisation of intangible assets and exchange differences on translation.

Inventories decreased to S\$1.43 million as at 31 March 2023 from S\$1.76 million as at 30 June 2022 mainly due to utilisation of the non-woven materials in the healthcare and healthcare consumables segment.

2. Review of performance of the Group (cont'd)

Financial Position Review (cont'd)

Non-current borrowings increased to \$\$0.98 million as at 31 March 2023 from \$\$0.51 million as at 30 June 2022 due to the reclassification from disposal group classified as held for sale.

Non-current lease liabilities increased to S\$0.37 million as at 31 March 2023 from S\$Nil million as at 30 June 2022 following a renewal of tenancy agreements in relation to the Group's office.

Trade and other payables increased to S\$10.71 million as at 31 March 2023 from S\$6.99 million as at 30 June 2022 mainly due to increase payable to creditors.

Current borrowings increased to S\$9.54 million as at 31 March 2023 from S\$9.53 million as at 30 June 2022 due to the reclassification from disposal group classified as held for sale.

Cash Flow Statement Review

Net cash flows generated from operating activities of S\$2.19 million in 3Q23 mainly due to positive operating cash flows in healthcare segment.

Net cash flows generated from investing activities amounted to S\$0.59 million mainly due to additions of intangible assets and net cash inflow from the disposal of subsidiary.

Net cash flows used in financing activities of S\$3.48 million were mostly to repay loans and lease liabilities and dividends paid to the non-controlling interests of the subsidiaries.

3. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

No forecast has been issued for the current financial reporting period.

4. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

As of the report's release date, the Company has made substantial progress in its restructuring initiatives. Over the past year, we have successfully divested our interests in all HSIM practices and all Traditional Chinese Medicine practices, and has disposed of most of the Group's practices held by HSID. Furthermore, key agreements have been executed with regards to Shanghai Fengwei, completion of which is ongoing and subject to shareholders' approval. The expeditious and efficient divestiture of these assets, optimising their value and mitigating liabilities, is a testament to the Group's commitment to prudent management.

The Group on 18 September, 2023 has proposed the acquisition of Tianjin Zhoushun Logistics Co., which indirectly holds 59% of Hequ Yuanyang Industrial Co., Ltd. primarily engaged in the business of coal storage and sales and general cargo loading and unloading. Please refer to our official public announcements for comprehensive details. As such, as at the date of this announcement, the Company has prepared this set of financial results for the financial period up to 31 March 2023 on the assumption that the Company and/or Group is able to continue as a going concern. The Company will make appropriate announcements accordingly when more information is available.

Please refer to Note 15 (Subsequent Events) above for further information on further factors and events that may affect the Group.

5. Dividend information

(a) Current financial period reported on

Any dividend recommended for the current financial period reported on?

None.

(b) Corresponding period of the immediate preceding financial year

Any dividend declared for the corresponding period of the immediately preceding financial year?

None.

(c) Date payable

Not applicable.

(d) Book closure date

Not applicable.

(e) If no dividend has been declared/recommend, a statement to the effect and the reasons for the decision

No dividend has been declared or recommend for the period ended 31 March 2023 due to accumulated losses of the Company.

6. Interested person transactions

Name of interested person	Aggregate value of all interested person transactions during the financial year under review (excluding transactions less than \$100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920)	Aggregate value of all interested person transactions conducted under the shareholders' mandate pursuant to Rule 920 (excluding transactions less than \$100,000)
	S\$'000	S\$'000
Interest expense:		
Mr Shen Yuyun	163	-
Rental:		
Shanghai Fengwei Nonwovens		
Co,. Ltd	531	-

For full disclosure, please note that there is an amount of S\$1.58 million owing from Shanghai Fengwei Nonwovens Co., Ltd. ("SFNW") a company majority owned by Mr Shen Yuyun (a substantial shareholder of the Company) to Shanghai Fengwei, a wholly owned subsidiary of the Company, which amount was owing prior to the Group's acquisition of Shanghai Fengwei. SFNW and New Silkroutes Capital Pte. Ltd., a wholly owned subsidiary, has entered into a lease agreement and the amount owing from SFNW will be used to offset against the rental payable by Shanghai Fengwei for the use of the land.

As disclosed in the announcement dated 21 July 2023, New Silkroutes Capital Pte. Ltd. ("NSC"), a wholly owned subsidiary of the Company, has entered into an Equity Transfer Agreement with Shanghai Yikang Non-Woven Fabric Co., Ltd. for the disposal of all of the shares held by NSC in Shanghai Fengwei, representing 100% of the total issued and paid up share capital of Shanghai Fengwei. The Company will make further announcements to update shareholders as and when there are material developments on the matter.

The Group does not have a general mandate for interested person transactions.

7. Disclosure on Acquisitions and Realisations of Shares pursuant to Rule 706A of the Listing Manual

Save as disclosed on SGXNet, during the period ended 31 March 2023, there were no acquisitions or realisations of shares resulting in a company becoming or ceasing to be a subsidiary or associated company of the Company, or resulting in the Company increasing or reducing its shareholding percentage in a subsidiary or associated company.

Please refer to Note 15 (Subsequent Events) above for subsequent acquisitions and disposals of shares carried out by the Group.

8. Negative assurance confirmation on the interim financial results pursuant to Rule 705(5) of the Listing Manual

On behalf of the Board of Directors of the Company, we, the undersigned, hereby confirm to the best of our knowledge that nothing has come to the attention of the Board of Directors of the Company which may render the condensed interim financial statements for the nine months ended 31 March 2023 to be false or misleading in any material respect.

On behalf of the Board of Directors

Darrell Lim Chee Lek Chua Siong Kiat
Independent Non-Executive Chairman Independent Non-Executive Director

9. Confirmation that the issuer has procured undertaking from all its directors and executive officers (in the format set out in Appendix 7.7) under Rule 720(1)

The Company has received undertaking from all its directors and executive officers in the format as set out in Appendix 7.7 under Rule 720(1) of the Listing Manual of the SGX-ST.

BY ORDER OF THE BOARD

Mr. Han Binke Executive Director and CEO 30 November 2023